John Forrest
Latest contributions
Hotline TAVI 3: Challenging anatomical and clinical scenarios
22 May 2025 – From EuroPCR 2025
This hotline session presents challenging anatomical and clinical scenarios in TAVI, including outcomes in bicuspid aortic valve patients, chronic aortic regurgigation, comparisons of surgical versus percutaneous approaches, and real-world data on valve performance and resource utilization.
Inludes:
- Five-year outcomes from the Evolut low risk TAVR bicuspid study
- Surgical versus...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
EuroPCR 2021 Hotlines / Late-Breaking Trials: SWENTRY, Redo-TAVI, Early neo2, PORTICO NG, and Evolut Low Risk Trial
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in TAVI:
- SWENTRY registry, Swedish Stroke Registry and National Patient Registry: late stroke after TAVI
- Redo-TAVI registry: implantation of a supplementary transcatheter aortic valve during TAVI
- Acurate neo2 TAVI valve results from the Early neo2 registry
- PORTICO NG: 30-day outcomes from a...
Complete 2-year follow-up from the Evolut low risk trial
18 May 2021 – From EuroPCR 2021
This session was originally presented during EuroPCR 2021.
